Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Spain
  4. Bolsas y Mercados Espanoles
  5. Pangaea Oncology, S.A.
  6. News
  7. Summary
    PANG   ES0105221008

PANGAEA ONCOLOGY, S.A.

(PANG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Vidaro Inversiones S.L. acquired 6.62% stake in Pangaea Oncology, S.A. from HERSOL XXI, SL for €1.5 million.

10/13/2020 EST

Vidaro Inversiones S.L. acquired 6.62% stake in Pangaea Oncology, S.A. (BME:PANG) from HERSOL XXI, SL for €1.5 million on October 13, 2020. Under the terms of transaction, Vidaro Inversiones purchased a total of 1.11 million securities of Pangaea Oncology at price of €1.36 for each Pangea share. Vidaro Inversiones S.L. completed the acquisition of 6.62% stake in Pangaea Oncology, S.A. (BME:PANG) from HERSOL XXI, SL on October 13, 2020.


© S&P Capital IQ 2020
All news about PANGAEA ONCOLOGY, S.A.
2021Pangaea Oncology, S.A. Reports Earnings Results for the Half Year Ended June 30, 2021
CI
2020Vidaro Inversiones S.L. acquired 6.62% stake in Pangaea Oncology, S.A. from HERSOL XXI,..
CI
2018Pangaea Oncology, S.A. announced that it has received €2.5 million in funding
CI
2018Pangaea Oncology, S.A. announced that it expects to receive €2.5 million in funding
CI
2018HERSOL XXI, SL acquired an additional 0.6% stake in Pangaea Oncology, S.A. from directo..
CI
2017GrupoPikolin, S.L. acquired 24.94% stake in Pangaea Oncology, S.A. from Mercantile Ebro..
CI
More news
Financials
Sales 2021 5,20 M 5,84 M 5,84 M
Net income 2021 -0,20 M -0,22 M -0,22 M
Net Debt 2021 0,40 M 0,45 M 0,45 M
P/E ratio 2021 -153x
Yield 2021 -
Capitalization 34,5 M 38,9 M 38,7 M
EV / Sales 2021 6,71x
EV / Sales 2022 5,08x
Nbr of Employees 50
Free-Float -
Chart PANGAEA ONCOLOGY, S.A.
Duration : Period :
Pangaea Oncology, S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PANGAEA ONCOLOGY, S.A.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 1,53 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Javier Rodríguez Rivela Chief Executive Officer & Director
Quentin Buraglio Chief Financial Officer
Rafael Rosell Costa Chairman & Chief Scientific Officer
Jesus Tejel Giménez Independent Director
Rafael López-Diéguez Independent Director
Sector and Competitors
1st jan.Capi. (M$)
PANGAEA ONCOLOGY, S.A.-2.55%39
MODERNA, INC.-39.94%61 847
LONZA GROUP AG-20.30%49 060
IQVIA HOLDINGS INC.-16.27%45 129
SEAGEN INC.-19.08%22 875
ICON PUBLIC LIMITED COMPANY-19.15%20 381